Recent Updates
Recently added Catalysts
AMIX Positive Sentiment Score: 75/100

Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Lunch Break: The Autonomix Opportunity

Key Takeaway: Autonomix Medical, Inc. (NASDAQ: AMIX) will participate in a Virtual Investor Lunch Break on February 29, 2024, featuring CEO Lori Bisson. The event aims to provide a corporate overview and discuss the company's innovative technologies for diagnosing and treating nervous system diseases. The company's leading technology platform offers significantly enhanced capabilities in detecting neural signals, with potential applications across various medical fields. Autonomix is initially focusing on solutions for pancreatic cancer pain while aiming to address multiple other indications.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in the Virtual Investor Lunch Break offers visibility.
  • Innovative technologies may revolutionize diagnosis and treatment.
  • The company's platform shows potential for addressing various diseases.
  • CEO Lori Bisson's involvement indicates strong leadership and vision.

Full Press Release Details

Live webcast with Lori Bisson, Chief Executive Officer of Autonomix, on Thursday, February 29th at 12:00 PM ET
THE WOODLANDS, TX, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will present at the Virtual Investor Lunch Break: The Autonomix Opportunity event on Thursday, February 29, 2024 at 12:00 PM ET.
As part of the event, Lori Bisson, Chief Executive Officer of Autonomix, will provide a corporate overview, business outlook, and discuss the Autonomix opportunity.
A live video webcast of the event will be available on the Events page under the Investors section of the Company’s website (autonomix.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing our technology for pancreatic cancer pain, a condition that can cause debilitating pain and needs an effective solution. However, our technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation and chronic pain management across a wide disease spectrum.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact

Tags

medical device company
innovative technologies
transvascular diagnosis

Frequently Asked Questions

When will the Autonomix webcast take place?

The Autonomix webcast is scheduled for February 29, 2024, at 12:00 PM ET.

Who will present during the Autonomix event?

Lori Bisson, the CEO of Autonomix, will be presenting at the event.

What will be discussed during the webcast?

The webcast will cover a corporate overview and business outlook regarding Autonomix.

How can I access the webcast replay?

The replay will be available two hours after the event for 90 days on their website.

What diseases does Autonomix aim to address?

Autonomix focuses on diagnosing and treating diseases of the nervous system, including pancreatic cancer pain.

Last updated: Feb 23, 2024